Table 2.
Association of serum IL-16 and risk of PCa among Caucasians.
| Tertile 1 | Tertile 2 vs Tertile 1 | Tertile 3 vs Tertile 1 | Continuous ln(IL-16) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| no. cases/ no. controls |
OR | 95% CI | p-value | no. cases/ no. controls |
OR | 95% CI | p-value | no. cases/ no. controls |
OR | 95% CI | p-value | p (trend) | OR | 95% CI | p-value | phet | |
| All PCa | 294/310 | 1.0 | reference | 309/324 | 1.02 | 0.81-1.29 | 0.83 | 329/308 | 1.13 | 0.89-1.42 | 0.31 | 0.31 | 1.07 | 0.95-1.21 | 0.27 | ||
| Nonaggressive PCa | 203/310 | 1.0 | reference | 208/324 | 1.04 | 0.80-1.35 | 0.76 | 227/308 | 1.11 | 0.86-1.44 | 0.43 | 0.44 | 1.06 | 0.92-1.22 | 0.40 | ||
| Aggressive PCa | 91/310 | 1.0 | reference | 99/324 | 1.04 | 0.74-1.45 | 0.83 | 102/308 | 1.24 | 0.89-1.74 | 0.21 | 0.21 | 1.13 | 0.94-1.35 | 0.19 | 0.54 | |
| Stage I/II PCa | 228/310 | 1.0 | reference | 246/324 | 1.06 | 0.83-1.36 | 0.63 | 257/308 | 1.11 | 0.87-1.42 | 0.40 | 0.41 | 1.06 | 0.93-1.21 | 0.40 | ||
| Stage III/IV PCa | 66/310 | 1.0 | reference | 63/324 | 0.94 | 0.64-1.38 | 0.77 | 72/308 | 1.21 | 0.83-1.77 | 0.33 | 0.33 | 1.14 | 0.92-1.40 | 0.23 | 0.52 | |
| Gleason Score ≤ 6 | 146/310 | 1.0 | reference | 138/324 | 1.00 | 0.74-1.33 | 0.98 | 128/308 | 0.92 | 0.68-1.24 | 0.57 | 0.58 | 0.91 | 0.78-1.06 | 0.22 | ||
| Gleason Score ≥ 7 | 145/310 | 1.0 | reference | 168/324 | 1.08 | 0.82-1.43 | 0.59 | 197/308 | 1.37 | 1.04-1.81 | 0.02 | 0.02 | 1.26 | 1.08-1.47 | 0.003 | 0.001 | |
| Time from blood draw to diagnosis/selection < 3 years | 133/126 | 1.0 | reference | 125/115 | 1.19 | 0.81-1.74 | 0.38 | 113/128 | 0.86 | 0.59-1.26 | 0.43 | 0.57 | 0.87 | 0.71-1.07 | 0.18 | ||
| Gleason Score ≤ 6 | 87/126 | 1.0 | reference | 74/115 | 1.08 | 0.70-1.67 | 0.72 | 76/128 | 0.92 | 0.60-1.42 | 0.71 | 0.71 | 0.83 | 0.66-1.04 | 0.11 | ||
| Gleason Score ≥ 7 | 46/126 | 1.0 | reference | 50/115 | 1.41 | 0.85-2.33 | 0.18 | 36/128 | 0.82 | 0.48-1.40 | 0.47 | 0.52 | 0.98 | 0.74-1.29 | 0.88 | 0.27 | |
| Time from blood draw to diagnosis/selection ≥ 3 years | 161/126 | 1.0 | reference | 184/210 | 1.01 | 0.75-1.36 | 0.94 | 216/180 | 1.41 | 1.04-1.90 | 0.03 | 0.02 | 1.24 | 1.06-1.46 | 0.008 | ||
| Gleason Score ≤ 6 | 59/184 | 1.0 | reference | 64/210 | 0.99 | 0.65-1.50 | 0.97 | 52/180 | 0.87 | 0.56-1.34 | 0.56 | 0.53 | 0.97 | 0.78-1.21 | 0.77 | ||
| Gleason Score ≥ 7 | 99/184 | 1.0 | reference | 118/210 | 1.03 | 0.73-1.45 | 0.87 | 161/180 | 1.78 | 1.27-2.49 | 0.001 | 0.001 | 1.44 | 1.19-1.74 | < 0.001 | 0.002 | |
All models adjusted for study center, use of thawed aliquot (yes/no), time from blood draw to diagnosis/selection, age and year at randomization.
Aggressive PCa defined as Gleason Score ≥8 or Stage III/IV disease.
Polytomous logistic regression
Time from blood draw to diagnosis/selection not adjusted for time from blood draw/selection